All In Biotech

Drug Trial Radar · NCT04885530

ACTIV-6: COVID-19 Study of Repurposed Medications

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,956 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,956

Actual

Start

Jun 8, 2021

Primary completion

Apr 29, 2024

Study completion Apr 29, 2024

Sponsor

Lead sponsor
Susanna Naggie, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center
First posted
May 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID. Pro00107921\_A - Arm D (Ivermectin 400) - NCT05736861; Pro00107921\_B - Arm B (Fluvoxamine) - NCT05890586; Pro00107921\_C - Arm C (Fluticasone) - NCT05736874; Pro00107921\_D - Arm D (Ivermectin 600) - NCT05894538; Pro00107921\_E - Arm E (Fluvoxamine 100) - NCT05894564; Pro00107921\_F - Arm F (Montelukast) - NCT05894577; Pro00107921\_G - Arm G (Metformin) - NCT06042855.

Conditions

  • Covid19

Interventions

  • IvermectinDrug

    Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with "123" over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.

  • FluvoxamineDrug

    Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has "APO" and the other side has "F50" with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.

  • FluticasoneDrug

    Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.

  • PlaceboOther

    Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.

  • MontelukastDrug

    Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.

  • MetforminDrug

    Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Number of Participants Randomized Within Each AppendixTime frame: Up to approximately 2 years 10 months

Locations

110 sites in 1 country. Site status is shown where the registry gives one.

  • Chandler Regional Medical Center

    Chandler, Arizona

  • Lamb Health, LLC

    Gilbert, Arizona

  • First Care Medical Clinic

    Mesa, Arizona

  • Trident Health Center

    Peoria, Arizona

  • University of Arkansas Medical Sciences

    Little Rock, Arkansas

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Assuta Family Medical Group APMC

    North Hollywood, California

  • Stanford

    Palo Alto, California

  • Olive View - UCLA Medical Center

    Sylmar, California

  • Doctors Medical Group of Colorado Springs, P.C.

    Colorado Springs, Colorado

  • Pine Ridge Family Medicine Inc.

    Colorado Springs, Colorado

  • Tabitha B. Fortt, M.D., LLC

    Stamford, Connecticut

  • George Washington University Hospital

    Washington D.C., District of Columbia

  • Arena Medical Group

    Deerfield Beach, Florida

  • Lupus Foundation of Gainesville

    Gainesville, Florida

  • University of Florida Health

    Gainesville, Florida

  • L and A Morales Healthcare, Inc

    Hialeah, Florida

  • University of Florida-JAX-ASCENT

    Jacksonville, Florida

  • AMRON Vitality and Wellness Center, LLC

    Jacksonville, Florida

  • Sunshine Walk In Clinic

    Lake Mary, Florida

  • Lakeland Regional Medical Center

    Lakeland, Florida

  • Jackson Memorial Hospital

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Well Pharma Medical Research

    Miami, Florida

  • The Angel Medical Research Corporation

    Miami Lakes, Florida

  • Innovation Clinical Trials Inc.

    Palmetto Bay, Florida

  • Lice Source Services Plantation

    Plantation, Florida

  • Premier Health

    St. Petersburg, Florida

  • Tallahassee Memorial Hospital

    Tallahassee, Florida

  • Tampa General Hospital

    Tampa, Florida

  • UF Health Precision Health Research

    The Villages, Florida

  • Morehouse School of Medicine

    Atlanta, Georgia

  • Emory Healthcare

    Atlanta, Georgia

  • Essential Medical Care, Inc.

    College Park, Georgia

  • Clincept, LLC

    Columbus, Georgia

  • HOPE Clinical Research and Wellness

    Conyers, Georgia

  • David Kavtaradze MD, Inc.

    Cordele, Georgia

  • Elite Family Practice

    Douglasville, Georgia

  • Christ the King Health Care, P.C.

    Loganville, Georgia

  • Miller Family Practice, LLC

    Macon, Georgia

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.